Thursday March 27, 2014

Sustained business growth: +11% in volume for kit sales

Financial performance is positively impacted by the implementation of pivotal agreements within the QIAGEN Group


Marseille, March 27, 2014 - QIAGEN Marseille (Alternext - FR0010626028 - ALIPS), a subsidiary of the QIAGEN Group (previously IPSOGEN), a cancer profiling company that develops, manufactures and markets molecular diagnostic tests for leukemia and cancer, today announced full-year 2013 results that were approved by the Board of Directors on March 20, 2014.

See press release

distributed by